AMENDMENTS TO THE CLAIMS

The following Listing of Claims will replace all prior versions of claims in the application:

Claims 1-2 (cancel)

Claim 3 (previously presented): A method to improve permeation of a pharmaceutically active substance across a cell barrier comprising co-administering the pharmaceutically active substance with compound 1:

and compound 2:

Claim 4 (currently amended): The method of claim 3, wherein compound 1 and compound 2 are present in a ratio of about 9:1 respectively.

Claim 5 (previously presented): The method of claim 3, wherein the pharmaceutically active substance is an antibiotic or antiparasitic compound.

Claim 6 (currently amended): The method of claim 5, wherein the <u>pharmaceutically active</u> substance <u>antibiotie</u> is a fluoroquinolone.

Claim 7 (currently amended): The method of claim 5, wherein the antiparasitic compound pharmaceutically active substance is mebendazole.

Claim 8 (currently amended): A composition to improve permeation of a pharmaceutically active substance across a cell barrier comprising compound 1:

and compound 2:

and a pharmaceutically acceptable carrier, wherein compound 1 and compound 2 are present in a ratio of about 9:1.

Claim 9 (new): The composition of claim 8, wherein compound 1 and compound 2 are present in a ratio of about 9:1.

Claim 10 (new): The method of claim 3, wherein the administration is enteral or parenteral.

Claim 11 (new): The method of claim 10, wherein the administration is an enteral administration selected from the group consisting of oral, nasal, or rectal.

Claim 12 (new): The method of claim 10, wherein the administration is a parenteral administration selected from the group consisting of intravenous, intraperitoneal, subcutaneous, and intramuscular.

Claim 13 (new): A method to improve permeation of a pharmaceutically active substance across the blood-brain barrier comprising co-administering the pharmaceutically active substance with compound 1:

and compound 2: